These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9740073)

  • 1. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
    Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
    Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
    Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
    Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
    Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis.
    Yamaguchi A; Goi T; Yu J; Hirono Y; Ishida M; Iida A; Kimura T; Takeuchi K; Katayama K; Hirose K
    J Surg Oncol; 2002 Apr; 79(4):230-5. PubMed ID: 11920780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma].
    Zhou DH; Ma ZM; Chen Y
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):833-7. PubMed ID: 18396641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
    Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
    Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
    Joo M; Lee HK; Kang YK
    Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
    Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
    Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis?
    Fasano M; Sabatini MT; Wieczorek R; Sidhu G; Goswami S; Jagirdar J
    Cancer; 1997 Jul; 80(1):34-41. PubMed ID: 9210706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
    Eisterer W; Bechter O; Söderberg O; Nilsson K; Terol M; Greil R; Thaler J; Herold M; Finke L; Günthert U; Montserrat E; Stauder R
    Leuk Res; 2004 Oct; 28(10):1043-51. PubMed ID: 15289016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
    Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
    Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
    Chang SM; Xing RD; Zhang FM; Duan YQ
    Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of T antigen expression in patients with gastric carcinoma.
    Chung YS; Yamashita Y; Kato Y; Nakata B; Sawada T; Sowa M
    Cancer; 1996 May; 77(9):1768-73. PubMed ID: 8646672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma.
    Ayhan A; Baykal C; Al A; Ayhan A
    Gynecol Oncol; 2001 Dec; 83(3):569-74. PubMed ID: 11733974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.